HS Pharmaceuticals, LLC is an early stage drug development company focusing on innovative immunotherapies for cancer treatment. Current pipeline programs include pre-clinical stage compounds for melanoma, pancreatic, breast, and lung cancers.
HS Pharma's novel, proprietary, patented compound HS-7, is an orally available small molecule that also lends itself to IV systemic delivery with demonstrated safety and efficacy in animal models. The company is seeking US and international development partners.
The company has a streamlined operational structure and utilizes best in class academic research labs, CRO's and industry experts to cost effectively advance its technology through the pre-clinical development process and into clinical trials.